QC Organisms for performance qualification of culture media
Quanti-Cult Plus™ quality control micro-organisms are ideal for use in pharmaceutical applications such as growth promotion testing and method validation.
Quanti-Cult Plus provides quality control organisms in an easy-to-use format, saving time and money. Quanti-Cult Plus consists of preserved American Type Culture Collection (ATCC®) strains and predispensed rehydration fluid, ready to use in QC procedures. It comes complete with full instructions for use and certificate of analysis, so no need to down load or print any documents before starting work. Simply open the box and go.
Quanti-Cult Plus is stored in the fridge, so is always close by, and even when reconstituted is stable for up to 8 hours at 2-8 °C. A full validation report is available on request.
Unlike some other systems, Quanti-Cult Plus complies with the pharmacopoeia recommendation for viable micro-organisms used in inoculation to not exceed five passages from the original master seed-lot, so avoiding the potential for phenotypical inconsistencies.
Quanti-Cult Plus ensures conformance to pharmacopoeia requirements (EP/USP/JP); each set reproducibly delivering
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
May 30th 2025In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Hesperos, Psilera Agree to Accelerate Organ-on-a-Chip Treatment for Frontotemporal Dementia
June 9th 2025The partnership leverages the Hesperos organ-on-a-chip platform in the preclinical development of Psilera’s lead compound targeting the progressive neurological disorder for which treatment options are few.
